Loading
SLC6A3 (Sodium-dependent dopamine transporter) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.
Mediates sodium- and chloride-dependent transport of dopamine. Also mediates sodium- and chloride-dependent transport of norepinephrine (also known as noradrenaline). Regulator of light-dependent retinal hyaloid vessel regression, downstream of OPN5 signalling.
Open Targets scores its association with cancer at 0.57 (direct and indirect evidence; datatypes literature 0.83, animal model 0.53, genetic association 0.00, clinical 0.88).
In plain words · SLC6A3 (Sodium-dependent dopamine transporter) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.
SLC6A3 (Sodium-dependent dopamine transporter) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.
Mediates sodium- and chloride-dependent transport of dopamine. Also mediates sodium- and chloride-dependent transport of norepinephrine (also known as noradrenaline).
No product in this corpus aims at SLC6A3 yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the role drug-target; HPA finds the RNA tissue enriched, which says where the protein sits but not whether the tumour differs from normal tissue. HPA SLC6A3: RNA tissue enriched (brain 93 nTPM); high antibody staining in 2 normal tissues; highest cancer staining thyroid cancer (1 of 4 high). Distribution: no corpus cancer carries a prevalence row, threshold or catalogue link for it; Open Targets associates it with 0 specific cancer types at or above 0.5. (No rule of scripts/fetch-target-specificity.ts fired.)
Sources: Human Protein Atlas SLC6A3 tissue; Open Targets ENSG00000142319 associations
First described 1992. Earliest sequence paper UniProt cites for the protein: Vandenbergh D.J. et al, Brain Res. Mol. Brain Res, 1992, "A human dopamine transporter cDNA predicts reduced glycosylation, displays a novel repetitive element and provides racially-dimorphic TaqI RFLPs". Source.
Sources: HGNC HGNC:11049 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q01959 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000142319 (association with cancer (MONDO_0004992) 0.57; (GraphQL API, CC0))
Mediates sodium- and chloride-dependent transport of dopamine. Also mediates sodium- and chloride-dependent transport of norepinephrine (also known as noradrenaline). Regulator of light-dependent retinal hyaloid vessel regression, downstream of OPN5 signalling. Location: Cell membrane; Cell projection, neuron projection; Cell projection, axon (UniProt). Locus 5p15.33 (HGNC).
RNA: tissue enriched (brain 93 nTPM), detected in single normal tissue.
RNA cancer enriched: Kidney Renal Clear Cell Carcinoma 7 pTPM.
Medium only: renal cancer.
HPA SLC6A3 tissue · HPA SLC6A3 pathology · HPA protein class: FDA approved drug targets
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"SLC6A3" OR ABSTRACT:"SLC6A3" OR TITLE:"solute carrier family 6 member 3" OR ABSTRACT:"solute carrier family 6 member 3" OR TITLE:"Sodium-dependent dopamine transporter" OR ABSTRACT:"Sodium-dependent dopamine transporter" OR TITLE:"DAT1" OR ABSTRACT:"DAT1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about SLC6A3, not a curated reading list.